Why use it

COPD is the third leading cause of death worldwide. Proper classification enables targeted pharmacological therapy: Group A patients benefit from short-acting bronchodilators alone, Group B from long-acting monotherapy (LABA or LAMA), and Group E from dual bronchodilator therapy (LABA + LAMA), with ICS added only for those with eosinophil ≥300 or frequent exacerbations. GOLD Grade correlates with physiological impairment, while ABE Group correlates with symptom burden and future exacerbation risk.

About

The GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria provide the international standard for classifying the severity of airflow obstruction in COPD and for guiding pharmacological management. The GOLD classification uses two components: (1) Spirometric Grade (GOLD 1–4) based on post-bronchodilator FEV1 % predicted in patients with FEV1/FVC < 0.70; and (2) ABE Risk Group (formerly ABCD) based on symptom burden (mMRC Dyspnea Scale or CAT score) and exacerbation history. The 2023 GOLD report updated the group classification from ABCD to ABE, merging groups C and D into group E to simplify the scheme and emphasize the primacy of exacerbation risk in driving escalation therapy. The combined GOLD Grade + ABE Group drives pharmacological treatment initiation and step-up decisions.

When to use

At diagnosis of COPD (post-bronchodilator FEV1/FVC < 0.70 on spirometry)
Annual reassessment of COPD severity and treatment appropriateness
After any change in clinical status — new exacerbation, hospitalization, or declining FEV1
Guiding initial pharmacological therapy for newly diagnosed COPD
Driving step-up or step-down decisions during COPD management reviews
Determining candidacy for pulmonary rehabilitation, lung volume reduction, or transplant

Formula

STEP 1 — SPIROMETRIC GRADE (post-bronchodilator FEV1 % predicted, with FEV1/FVC < 0.70): GOLD 1 (Mild): FEV1 ≥ 80% predicted GOLD 2 (Moderate): FEV1 50–79% predicted GOLD 3 (Severe): FEV1 30–49% predicted GOLD 4 (Very Severe): FEV1 < 30% predicted STEP 2 — ABE GROUP (2023 GOLD): Group A: 0–1 moderate exacerbations (no hospitalization) + mMRC 0–1 or CAT < 10 Group B: 0–1 moderate exacerbations (no hospitalization) + mMRC ≥ 2 or CAT ≥ 10 Group E: ≥2 moderate exacerbations OR ≥1 hospitalized exacerbation (regardless of symptoms) Initial Pharmacotherapy: Group A → Short-acting bronchodilator (SABA/SAMA) Group B → LABA or LAMA (prefer LAMA) Group E → LABA + LAMA; consider adding ICS if eos ≥300 or frequent exacerbations

Pearls & pitfalls

The 2023 GOLD update merges Groups C and D into Group E — the old 4-box ABCD matrix is now a 3-group ABE system.
FEV1/FVC < 0.70 is used for diagnosis — the LLN (lower limit of normal) method may be preferred in elderly patients to reduce over-diagnosis.
GOLD Grade is based on post-bronchodilator spirometry — ALWAYS use the post-BD value for classification.
Exacerbation history is the MOST IMPORTANT driver of group classification — even mild FEV1 impairment (GOLD 1) with ≥2 exacerbations = Group E.
One hospitalization for exacerbation counts the same as ≥2 moderate exacerbations in the ABE group assignment.
The mMRC scale captures dyspnea, while the CAT captures overall symptom impact — either can be used for group assignment.
ICS monotherapy should NOT be used in COPD — always combine ICS with a LABA at minimum.
Blood eosinophil count >300/μL predicts ICS response and reduces exacerbation risk; <100/μL suggests poor ICS response.
Alpha-1 antitrypsin deficiency should be excluded in patients with COPD before age 45 or with strong family history.

Next steps

Group A: Short-acting bronchodilator (SABA or SAMA) PRN. Group B: Long-acting bronchodilator monotherapy (LABA or LAMA; prefer LAMA for exacerbation prevention). Group E: LABA + LAMA dual bronchodilator therapy. Consider adding ICS if: blood eosinophils ≥300/μL, or ≥2 moderate exacerbations/year despite dual bronchodilation. All patients: smoking cessation, influenza vaccine, pneumococcal vaccine, pulmonary rehabilitation, COVID-19 vaccination. Assess comorbidities (cardiovascular disease, osteoporosis, anxiety/depression). Oxygen therapy if resting SpO2 ≤88% or PaO2 ≤55 mmHg. GOLD 3–4: Refer to pulmonologist.

Evidence

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2024 Report. PMID (GOLD original report): 11734290. TORCH trial (salmeterol/fluticasone): Calverley PM et al. NEJM 2007. UPLIFT trial (tiotropium): Tashkin DP et al. NEJM 2008. IMPACT trial (fluticasone/umeclidinium/vilanterol triple therapy): Lipson DA et al. NEJM 2018.

References

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2024 Report. — link
Agustí A et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023;61(4):2300239. — link
Lipson DA et al. Triple Therapy with Budesonide-Glycopyrrolate-Formoterol for COPD. N Engl J Med. 2018;378(18):1671-1680. — link

GOLD Criteria for COPD

Calculator